Effects of 24 Weeks of Growth Hormone Treatment on Bone Microstructure and Volumetric Bone Density in Patients with Childhood-Onset Adult GH Deficiency

Table 2

Baseline and follow-up of endocrinological and biochemical parameters.

	Baseline	24-week follow-up	Changes	value
IGF-1 (ng/ml)	78.1 ± 59.3	125.6 ± 75.6	47.43 ± 62.04	0.090
IGF-1 SDS	−3.31 ± 1.56	−1.92 ± 1.65	1.38 ± 1.97	0.113
FT3 (pg/mL)	2.81 ± 0.61	2.86 ± 0.85	0.04 ± 0.75	0.880
FT4 (ng/dL)	1.04 ± 0.18	0.81 ± 0.26	−0.23 ± 0.21	0.024
Glu (mmol/L)	4.98 ± 0.62	4.73 ± 0.75	−0.24 ± 0.59	0.250
Hb (g/L)	151.9 ± 7.9	148.0 ± 9.0	−3.89 ± 8.25	0.195
ALT (U/L)	18.6 ± 7.2	19.1 ± 11.1	−3.00 (−8.00, 32.00)	0.895
AST (U/L)	24.0 ± 4.2	24.9 ± 6.0	−0.50 (−4.00, 15.00)	0.713
GGT (U/L)	19.5 ± 5.1	16.1 ± 3.9	−3.38 ± 4.44	0.069
ALP (U/L)	83.6 ± 38.6	120.5 ± 63.7	36.88 ± 42.80	0.045
Alb (g/L)	47.6 ± 3.6	47.4 ± 2.8	0.00 (−6.00, 2.00)	0.802
PA (mg/L)	263.0 ± 39.5	259.5 ± 36.5	−3.50 ± 22.90	0.769
Tbil (μmol/L)	9.9 ± 3.6	13.0 ± 3.7	3.02 ± 3.09	0.022
Dbil (μmol/L)	3.5 ± 1.4	4.6 ± 1.6	1.13 ± 0.88	0.008
Ca (mmol/L)	2.37 ± 0.08	2.41 ± 0.13	0.04 ± 0.11	0.365
P (mmol/L)	1.17 ± 0.17	1.35 ± 0.18	0.18 ± 0.19	0.030
25OHD (ng/ml)	22.05 ± 8.56	17.78 ± 7.72	−4.28 ± 5.34	0.032
PTH (pg/ml)	51.45 ± 19.72	45.12 ± 26.22	−6.33 ± 37.24	0.586
β-CTX (ng/ml)	0.67 ± 0.32	1.09 ± 0.58	0.42 ± 0.48	0.022
Cr (μmol/L)	74.1 ± 8.3	77.1 ± 8.7	3.00 ± 7.50	0.264
UA (μmol/L)	438.5 ± 78.6	404.4 ± 71.1	−34.13 ± 70.57	0.214

Data are presented as mean ± SD or median and ranges. IGF-1, insulin like growth factor 1; FT3, free triiodothyronine; FT4, free thyroxine; Glu, glucose; Hb, hemoglobin; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; Alb, albumin; PA, prealbumin; Tbil, total bilirubin; Dbil, direct bilirubin; Ca, calcium; P, phosphate; 25OHD, 25 hydroxy-vitamin D; PTH, parathyroid hormone; β-CTX, β-C-terminal telopeptide region of collagen type 1; Cr, creatinine; UA, uric acid.